2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-[3-(propan-2-yloxy)phenyl]-3,4-dihydroquinazolin-4-one

• ChemBase ID: 154350
• Molecular Formular: C27H24BrN3O2
• Molecular Mass: 502.40236
• Monoisotopic Mass: 501.10518902
• SMILES: CC(C)Oc1cccc(c1)n1c(nc2ccccc2c1=O)CCc1c[nH]c2c1cc(cc2)Br
• Canonical SMILES: CC(Oc1cccc(c1)n1c(CCc2c[nH]c3c2cc(Br)cc3)nc2c(c1=O)cccc2)C
• InChI: InChI=1S/C27H24BrN3O2/c1-17(2)33-21-7-5-6-20(15-21)31-26(30-25-9-4-3-8-22(25)27(31)32)13-10-18-16-29-24-12-11-19(28)14-23(18)24/h3-9,11-12,14-17,29H,10,13H2,1-2H3
• InChIKey: KUECXUACQOYKNB-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-[3-(propan-2-yloxy)phenyl]-3,4-dihydroquinazolin-4-one
• IUPAC Traditional name: 2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-(3-isopropoxyphenyl)quinazolin-4-one
• Synonyms: 2-[2-(5-Bromo-1H-indol-3-yl)ethyl]-3-[3-(1-methylethoxy )phenyl]-4-(3H)-quinazolinone; LY225910

Database IDs

• CAS Number: 133040-77-4
• MDL Number: MFCD00907856
• PubChem SID: 162248489
• PubChem CID: 4355450

CALCULATED PROPERTIES

• Acid pKa: 16.918728
• H Acceptors: 3
• H Donor: 1
• LogD (pH = 5.5): 6.4172096
• LogD (pH = 7.4): 6.4172096
• Log P: 6.4172096
• Molar Refractivity: 135.727 cm^3
• Polarizability: 52.004513 Å^3
• Polar Surface Area: 57.69 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: DMSO: >20 mg/mL
• Apperance: off-white powder
• Flash Point: 337 - 405 °C; 638.6 - 761 °F

Safety Information

• European Hazard Symbols: Harmful (Xn)
• UN Number: 2811
• German water hazard class: 3
• Hazard Class: 6.1
• Packing Group: 3
• Risk Statements: 22
• GHS Pictograms: GHS06
• GHS Signal Word: Danger
• GHS Hazard statements: H301-H413
• GHS Precautionary statements: P301 + P310
• RID/ADR: UN 2811 6.1/PG 3
• Storage Temperature: 2-8°C

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C27H24BrN3O2

DETAILS

Sigma Aldrich - L2545

Biochem/physiol Actions
Cholecystokinin is expressed in the gastrointestinal tract and the central nervous system. Cholecystokinin receptor type 2 (CCK2) is a GPCR that is highly expressed in brain and spinal cord. CCK2 is implicated in many brain processes, including mood, anxiety, and pain, through its modulation of GABA neurotransmission.LY225910 is a potent, selective CCK2 antagonist. LY225910 blocks agonism of CCK2 by CCK-8S, the peptide agonist. LY225910 has been measured in multiple systems, including GABA efflux from cortical cultures, depolarization of spinal cord neurons (via potassium conductance), modulation of excitatory postsynaptic potentials (EPSPs) in nucleus accumbens slices, and enhancement of morphine analgesia.